LentitiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system based on tumor suppressor gene BRD7 as well as preparation and application of LentitiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system

By constructing the LentiCRISPRv2/dCas9-TET1CD-sgRNAs gene editing system, targeting the hypermethylated region of the BRD7 promoter region for demethylation, successfully activate BRD7 expression, solving the problem of short-term demethylation effect in the prior art, significantly It inhibits the proliferation and tumor growth of a variety of tumor cells.

CN118910169APending Publication Date: 2024-11-08CENT SOUTH UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410997598.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-24
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing gene editing technologies are difficult to achieve long-term and continuous demethylation effects in tumor cells, resulting in downregulation of BRD7 gene expression and affecting the effectiveness of tumor treatment.

Method used

The LentiCRISPRv2/dCas9-TET1CD-sgRNAs gene editing system was constructed, and the BRD7 promoter region was targeted for demethylation editing, and the dCas9-TET1CD protein and specific sgRNAs were combined to achieve continuous activation and expression of BRD7.

Benefits of technology

It significantly improved the mRNA and protein expression levels of BRD7, inhibited the proliferation of various tumor cells such as nasopharyngeal carcinoma and breast cancer and tumor growth in the body, and provided a potential targeted therapy strategy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910169A_ABST
    Figure CN118910169A_ABST
Patent Text Reader

Abstract

The invention discloses a LentitiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system based on a tumor suppressor gene BRD7 as well as a preparation method and application of the LentitiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system. Specifically, down-regulation of expression of the BRD7 is closely related to high methylation modification of a CpG island region of a promoter region of the BRD7, and the CpG island high methylation region of the promoter region of the BRD7 can be specifically demethylated through traction of the sgRNAs, so that expression of the cancer suppressor gene BRD7 is activated, and individualized precise treatment of tumor patients is realized. Therefore, a LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system is constructed on the basis of lentivirus delivery and a dCas9 directionally-guided demethylation technology, is used for activating BRD7 expression, and can remarkably inhibit proliferation of tumor cells such as nasopharynx cancer and breast cancer and growth of in-vivo tumors, so that an anti-tumor effect is shown, and the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system is expected to become an important molecular strategy for individualized treatment of tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of tumor molecular biology, and specifically relates to a LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system for demethylating a CpG island hypermethylated region in a BRD7 promoter region and thereby activating the expression of a tumor suppressor gene BRD7, and a preparation method thereof, and also relates to the application of the gene editing system in the preparation of tumor therapeutic preparations. Background Art

[0002] The occurrence of tumors is the result of the combined effects of environmental and genetic factors, and is more of a multi-stage pathological process involving multiple factors. The current progress in cancer treatment is far from satisfactory. Clinical treatment is mainly based on surgery and radiotherapy and chemotherapy, and when necessary, it will also be combined with targeted therapy, biological therapy and other methods. Gene therapy is an ideal treatment method. It is a biomedical technology that introduces a gene sequence with therapeutic effects into the body's target cells in a certain way, and achieves therapeutic effects through high-level expression of transgenic genes. It is an important part of biological therapy. With the understanding and clarification of the pathogenesis of malignant tumors at the genetic level, and the increasing perfection and maturity of molecular cloning and gene transfer technology, gene therapy as a treatment method has been increasingly accepted in the clinic and a large number of new drug clinical studies have been conducted.

[0003] The BRD7 gene is a full-length new gene that is lowly expressed in nasopharyngeal carcinoma cells that was independently isolated and cloned by the research team through cDNA representative difference analysis, library screening and other methods. It has been confirmed that it plays an important tumor suppressor function in a variety of malignant tumors such as nasopharyngeal carcinoma, breast cancer, and lung cancer, and is negatively correlated with the clinical progression and poor prognosis of tumors. However, the mechanism of downregulation of BRD7 expression in multiple tumors such as nasopharyngeal carcinoma and breast cancer is not fully understood. Studies have shown that epigenetic modifications play an important role in the regulation of gene expression. Epigenetic modifications such as DNA methylation and histone modification regulate chromatin structure. Any aberration will change the chromosome structure, leading to abnormal gene expression and pathological changes. DNA methylation usually occurs on CpG islands and silences gene expression by inhibiting the binding of transcription factors to promoters or recruiting methylation-CpG binding proteins to bind to inhibitory histone modification enzymes. It has been proven that DNA methylation is associated with many diseases, including tumors and imprinting diseases. In tumors, DNA methylation in the promoter region of tumor suppressor genes is an important mechanism leading to the downregulation of tumor suppressor gene expression and the occurrence and development of tumors. It has been identified that multiple genes such as Rb, p16, PTEN, VHL, p57, BRCA1, etc. have high methylation modifications in the corresponding tumors. Therefore, they are potential diagnostic and prognostic markers and are considered to be cancer markers for many tumor types. However, research on BRD7 gene methylation in multiple tumors such as nasopharyngeal carcinoma, breast cancer, and lung cancer is still limited.

[0004] DNA demethylation has been considered a passive process, but the discovery of TET family proteins provides an active demethylation process. TET proteins all contain a conserved double-stranded β-helix (DSBH) domain, a cysteine-rich domain, and binding sites for auxiliary factors Fe(II) and 2-oxogluconate (2-OG), which together form the core catalytic region at the C-terminus. Structural studies have shown that the core catalytic region preferentially binds to cytosine in a CpG context, but does not interact with the surrounding DNA bases and has no specificity for flanking DNA sequences. The TET1 gene was first discovered and identified as a partner gene fused to the MLL gene. In 2009, it was found that it can act as a dioxygenase, converting 5mC to 5hmC, and further converting it to 5-formylcytosine and 5-carboxycytosine to complete demethylation. Subsequently, 5-formylcytosine and 5-carboxycytosine are removed by the cell DNA repair mechanism, regenerating unmethylated cytosine, achieving the reversal of methylation status and regulating gene expression. Previous studies have shown that BRD7 is epigenetically and transcriptionally regulated; therefore, we reasoned that transcriptional reactivation of BRD7 expression in tumor cells is feasible.

[0005] In the past 20 years, genome editing technology has made great progress. The CRISPR / Cas9 system has quickly become the most popular genome editing platform due to its simplicity and strong adaptability. The progress of CRISPR / Cas9 technology has also made various applications of nuclease-deficient Cas9 (dCas9) possible. It can bind to specific regions of the genome, not only inheriting the precision of the CRISPR / Cas9 system, but also showing good effects. In this system, the dCas9 protein retains the ability of the Cas9 protein to bind to DNA, but the cutting function no longer exists. Recent studies have shown that the fusion of dCas9 protein with the catalytic domains of various effector proteins to produce CRISPR activators (CRISPRa) or inhibitors (CRISPRi) can activate or silence the expression of target genes, such as DNA demethylase TET1, transcription activator VP64, transcription repressor effector KRAB, etc., can demethylate, activate or inactivate genes, and precisely regulate gene expression and epigenetic modifications. Therefore, different epigenetic modification systems based on the CRISPR / dCas9 system have important research value in the field of human disease treatment and cancer research. However, the dual-plasmid system is still widely used. Although it can perform targeted DNA demethylation, the demethylation effect is short-lived and cannot achieve long-term effects in the body. The LentiCRISPRv1 / dCas9 plasmid adapted from the CRISPR / Cas9 plasmid of Zhang Feng et al. can constitutively express sgRNA and can achieve continuous intervention on the target gene, but this plasmid system still has shortcomings such as low viral assembly efficiency and weak cell infection ability. The newly developed LentiCRISPRv2 vector (Addgene#52961) on the market can produce viruses with a titer about 10 times higher than LentiCRISPRv1, and has more obvious advantages in target gene delivery and targeted recognition. Therefore, in the present invention, we first constructed the LentiCRISPRv2 / dCas9-TET1CD plasmid based on the original LentiCRISPRv1 / dCas9 plasmid and LentiCRISPRv2, and connected the sgRNAs specifically targeting the hypermethylated modification region of the BRD7 promoter to the plasmid system, thereby successfully constructing the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system specifically targeting the hypermethylated modification region of the BRD7 promoter. Therefore, the modified LentiCRISPRv2 / dCas9-TET1CD-sgRNAs plasmid can constitutively express the sgRNA and dCas9-TET1CD fusion protein, thereby achieving the targeting, continuous demethylation and transcriptional activation of the target gene.

[0006] In the present invention, we confirmed that there is CpG island hypermethylation in the BRD7 promoter region. In addition, tumor cell lines treated with decitabine, a potent inhibitor of DNA methyltransferase, showed that the methylation level of the BRD7 promoter was significantly reduced, while the mRNA and protein expression levels of BRD7 were significantly increased. This clearly shows that DNA methylation at the BRD7 promoter is a key mechanism for downregulating BRD7 expression. Therefore, targeting the specific methylation sites of the CpG island in the BRD7 promoter region, we modified the LentiCRISPRv2 vector and constructed the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system to perform targeted DNA demethylation editing and transcriptional activation on the highly methylated region of the BRD7 gene promoter region. The results showed that under the traction of sgRNA2 and sgRNA5, the LentiCRISPRv2 / dCas9-TET1CD system can promote the demethylation of the BRD7 promoter region and the expression of BRD7 mRNA and protein in multiple tumor cells such as nasopharyngeal carcinoma and breast cancer, thus proving the effectiveness and broad spectrum of the system in activating BRD7 expression in multiple tumors. The results of in vitro and in vivo experiments showed that the gene editing system can significantly inhibit the proliferation of multiple tumor cells such as nasopharyngeal carcinoma and breast cancer and the growth of tumors in vivo, thus showing an anti-tumor effect. These results suggest that the construction of the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system and the preparation of tumor therapeutic preparations can be used for clinical targeted treatment of patients with tumors with low BRD7 expression, and is expected to become an important molecular strategy for personalized tumor treatment. Summary of the invention

[0007] The primary purpose of the present invention is to provide a preparation method of the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system, which is mainly applied to lentiviral delivery and dCas9-directed demethylation technology, and it is confirmed that the system can effectively activate the expression of BRD7 in tumor cells such as nasopharyngeal carcinoma, breast cancer, lung cancer, cervical cancer, etc. and inhibit the proliferation of tumor cells and tumor growth in vivo, and can be used for targeted or adjuvant treatment of patients with tumors with low BRD7 expression.

[0008] The method for constructing the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system includes the following steps:

[0009] The Cas9 sequence of the LentiCRISPRv2 plasmid (purchased from Addgene #52961) was replaced with dCas9-TET1CD-EGFP to obtain the LentiCRISPRv2 / dCas9-TET1CD vector; sgRNAs specifically targeting the highly methylated region of the CpG island of the BRD7 promoter were further connected to the LentiCRISPRv2 / dCas9-TET1CD vector.

[0010] The construction method specifically comprises:

[0011] (1) First, the LentiCRISPRv2 vector is digested with enzymes to remove the Cas9 element in the LentiCRISPRv2 vector, and the LentiCRISPRv2-△Cas9 fragment with Cas9 removed is recovered by gel;

[0012] (2) PCR amplification of dCas9-TET1CD-EGFP sequence (sequence see SEQ NO: 1);

[0013] (3) connecting the LentiCRISPRv2-△Cas9 fragment from which Cas9 was removed in step (1) with the dCas9-TET1CD-EGFP fragment amplified in step (2) to construct a LentiCRISPRv2 / dCas9-TET1CD vector;

[0014] (4) Designing sgRNAs targeting the highly methylated region of the CpG island of the BRD7 promoter based on the target gene sequence; annealing the single-stranded sgRNA to form a double-stranded sgRNA;

[0015] (5) BsmBI digestion step (3) constructed LentiCRISPRv2 / dCas9-TET1CD vector;

[0016] (6) The long fragment product recovered after enzyme digestion in step (5) is connected to the double-stranded sgRNA formed by annealing in step (4) to obtain LentiCRISPRv2 / dCas9-TET1CD-sgRNAs.

[0017] Furthermore, the construction method specifically includes:

[0018] First, the LentiCRISPRv2 vector was double-digested with Xba I and BamH I to remove the Cas9 element in the LentiCRISPRv2 vector, and the fragment LentiCRISPRv2-△Cas9 was recovered by gel-gel;

[0019] Then PCR amplified the dCas9-TET1CD-EGFP sequence;

[0020] The LentiCRISPRv2-△Cas9 fragment was connected to the dCas9-TET1CD-EGFP fragment using T4 DNA ligase to construct the LentiCRISPRv2 / dCas9-TET1CD vector;

[0021] Design an sgRNA sequence targeting the highly methylated region of the CpG island of the BRD7 promoter based on the target gene sequence, and anneal the single-stranded sgRNA to form a double-stranded sgRNA;

[0022] Digest the constructed LentiCRISPRv2 / dCas9-TET1CD plasmid with BsmBI;

[0023] T4 DNA ligase was used to ligate the product recovered after digestion of LentiCRISPRv2 / dCas9-TET1CD plasmid with the double-stranded sgRNA formed by annealing.

[0024] Furthermore, the PCR amplification primer sequences were:

[0025] Upstream primer sequence: 5′-GCTCTAGAATGAGCCCCAAGAAGAAG-3′;

[0026] Downstream primer sequence: 5′-CGCGGATCCTTCTTACTTGTACAGCTCGTCCAT-3′;

[0027]

[0028] The constructed LentiCRISPRv2 / dCas9-TET1CD vector plasmid was transformed into DH5α Escherichia coli competent cells, and single clones were picked for resistance screening. The bacterial liquid PCR was used to detect whether the dCas9-TET1CD-EGFP fragment was successfully inserted into the lentiCRISPRv2-△Cas9 vector;

[0029] The product recovered after restriction digestion of LentiCRISPRv2 / dCas9-TET1CD plasmid and the ligation product of double-stranded sgRNA formed by annealing were used for DH5α E. coli transformation, resistance screening, picking single clones, and sequencing to determine whether the sgRNA was successfully inserted into the LentiCRISPRv2 / dCas9-TET1CD vector.

[0030] The construction method described,

[0031] The preparation of the lentiviral system mainly includes: viral packaging plasmids psPAX2 and pMD2.G, reagent polyplus required for transfection of the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system, and viral concentrate PEG8000.

[0032] Furthermore, other conventional reagents required for preparing lentiviral supernatant expressing LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system: virus concentrate 5×PEG8000, normal saline, DH5α competent bacteria; LB liquid culture medium; tryptone; yeast extract; Tiangen endotoxin-free plasmid mini-preparation kit.

[0033] The present invention also provides a LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system, which is prepared by the described method.

[0034] The present invention also provides an application of the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system to prepare a tumor treatment preparation.

[0035] The tumors include: nasopharyngeal carcinoma, breast cancer, lung cancer, cervical cancer and other tumor types in which BRD7 is lowly expressed.

[0036] Preferably, the therapeutic preparation includes: LentiCRISPRv2 / dCas9-TET1CD-sgRNA2, LentiCRISPRv2 / dCas9-TET1CD-sgRNA5 and a mixture thereof.

[0037] The present invention also provides a second application of the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system, which is to prepare a preparation for activating the tumor suppressor gene BRD7.

[0038] The tumor therapeutic preparation expressing the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system is mainly administered by local tumor injection, and other administration routes are not excluded to achieve the treatment of the tumor target site.

[0039] The present invention confirmed that BRD7 expression was significantly downregulated in tumor tissues through RT-qPCR and Western Blot experiments. In order to further explore the reasons for the downregulation of BRD7 expression, we predicted through the EMBOSS website and MethPrimer website and confirmed through methylation-specific PCR that there was CpG island hypermethylation in the BRD7 promoter region, which was negatively correlated with the expression of BRD7, indicating that epigenetic modification is one of the key mechanisms leading to the downregulation of BRD7 expression. Therefore, in order to activate the expression of BRD7, we modified the CRISPR / Cas9 system and constructed the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system that specifically targets the highly methylated region of the CpG island in the BRD7 promoter region. The results showed that the system had a good BRD7 activation effect, among which LentiCRISPRv2 / dCas9-TET1CD-sgRNA2 and LentiCRISPRv2 / dCas9-TET1CD-sgRNA5 had the most significant activation effects. Consistent results were obtained in multiple tumors such as nasopharyngeal carcinoma and breast cancer, confirming that the gene editing system has a broad spectrum. Both in vitro and in vivo experiments confirmed that the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system can inhibit the proliferation and cloning ability of tumor cells and the growth of tumors in vivo, indicating that the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system can demethylate the CpG island hypermethylated region of the BRD7 promoter region and activate the expression of BRD7, which can make up for the deficiency of BRD7 in tumor cells and can be used to prepare preparations for tumor treatment. Therefore, the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system prepared by the present invention helps to further clarify the transcriptional inhibition mechanism of the BRD7 gene in tumor cells, and provides a powerful molecular biology tool for the individualized treatment of patients with tumors with low BRD7 expression, which has important clinical value and transformation application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] Figure 1 The expression of BRD7 is downregulated in tumor patient tissues, which is negatively correlated with the high methylation level of the promoter region;

[0041] AC: (A) RT-qPCR experiment (B) Western Blot experiment (C) Agarose gel electrophoresis to detect the expression level of BRD7 in non-cancer patients and tumor patients;

[0042] D: The size, location and methylation status of the CpG island in the BRD7 promoter region (2000 bp upstream of the transcription start site) predicted by the EMBOSS website and the MethPrimer website;

[0043] E: methylation-specific PCR primer positions;

[0044] F: Methylation-specific PCR detected the methylation level of the BRD7 promoter region in normal epithelial cells and tumor cells;

[0045] G: Diagram of the mechanism of action of decitabine;

[0046] H, I: RT-qPCR experiment (H) and Western Blot experiment (I) were used to detect the effect of decitabine treatment on BRD7 mRNA expression and protein expression levels;

[0047] J: Methylation-specific PCR was used to detect the effect of decitabine treatment on the methylation level of CpG island in the BRD7 promoter region.

[0048] *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, no statistical difference.

[0049] Figure 2 The construction process of the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system targeting the hypermethylated region of the BRD7 CpG island;

[0050] A: Schematic diagram of the construction process of the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system;

[0051] B: Xba I and BamH I double-digested the LentiCRISPRv2 vector to remove the Cas9 element;

[0052] C: Agarose gel electrophoresis to detect gel-recovered fragment LentiCRISPRv2-△Cas9;

[0053] D: Agarose gel electrophoresis detection of PCR products of dCas9-TET1CD-EGFP fragment;

[0054] E: Agarose gel electrophoresis detection of PCR purified products of dCas9-TET1CD-EGFP fragment;

[0055] F: Bacterial liquid PCR detection of plasmid LentiCRISPRv2 / dCas9-TET1CD-EGFP to determine whether it was successfully constructed;

[0056] G: BsmBI-digested plasmid LentiCRISPRv2 / dCas9-TET1CD-EGFP;

[0057] H: Gel recovery of the long fragment of the BsmBI-digested plasmid LentiCRISPRv2 / dCas9-TET1CD-EGFP;

[0058] I: Sanger sequencing detected whether the sgRNAs (sgRNA1-sgRNA5) were successfully connected into the vector LentiCRISPRv2 / dCas9-TET1CD-EGFP.

[0059] Figure 3 To detect the effect of LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system on BRD7 expression

[0060] A: Distribution of sgRNAs (sgRNA1-sgRNA5) in the CpG island region of the BRD7 promoter;

[0061] B: Schematic diagram of the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system to activate BRD7;

[0062] C, D: RT-qPCR experiments (C) and Western Blot experiments (D) detected the effects of the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system on BRD7 mRNA and protein expression levels.

[0063] Figure 4 To examine the effect of co-delivery of LentiCRISPRv2 / dCas9-TET1CD-sgRNA2 and LentiCRISPRv2 / dCas9-TET1CD-sgRNA5 on BRD7 expression

[0064] AD: RT-qPCR experiments (A, C) and Western Blot experiments (B, D) detected the effects of combined delivery of sgRNA2 and sgRNA5 on the expression levels of BRD7 mRNA and protein in nasopharyngeal carcinoma cells and breast cancer cells.

[0065] Figure 5 Functional assay for inhibiting tumor cell growth by overexpressing LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system in vitro;

[0066] A: CCK-8 assay was used to detect the effect of overexpression of LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system (stable expression of sgRNA2 and sgRNA5 alone or combined delivery of the two) on the proliferation ability of nasopharyngeal carcinoma cells (5-8F and CNE2) and breast cancer cells (MDA-MB-231 and MCF7);

[0067] B: Cloning experiments showed that the overexpression of LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system (stable expression of sgRNA2 and sgRNA5 alone or combined delivery of the two) affected the cloning ability of nasopharyngeal carcinoma cells (5-8F and CNE2) and breast cancer cells (MDA-MB-231 and MCF7).

[0068] Figure 6 Phenotypic detection to confirm that the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system inhibits tumor growth in vivo

[0069] A: Nasopharyngeal carcinoma cells CNE2 / LentiCRISPRv2 / dCas9-TET1CD-sgNC, CNE2 / LentiCRISPRv2 / dCas9-TET1CD-sg2, CNE2 / LentiCRISPRv2 / dCas9-TET1CD-sg5 and CNE2 / LentiCRISPRv2 / dCas9-TET1CD-sg2+5 were injected into the subcutaneous area above the axilla of the right forelimb of nude mice, and the size of the transplanted tumor was measured every 3 days;

[0070] B: After 30 days, the nude mice were killed and the tumors were removed. It was observed that the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system could significantly inhibit the growth of transplanted tumors;

[0071] C: Weigh the transplanted tumors in the control group and each experimental group.

[0072] D: Immunohistochemistry experiments were used to detect the expression of BRD7 and some cell proliferation, cycle and apoptosis-related molecules in the tumor of nude mice in each group.

[0073] Figure 1-6 The sg2 and sg5 appearing in are sgRNA2 and sgRNA5 respectively. DETAILED DESCRIPTION

[0074] The present invention is further described below in conjunction with specific embodiments, but is not intended to limit the present invention.

[0075] The non-cancerous patient tissues and tumor patient tissue specimens used in the present invention were all from patients of the Second Xiangya Hospital of Central South University. The relevant clinical data of all patients were collected, and the collection of all experimental tissue samples was authorized by the Central South University Ethics Committee and the patients agreed.

[0076] The tumor cell lines used in the present invention are all preserved in the Molecular Genetics Laboratory of the Tumor Research Institute of Central South University. The cell culture conditions are: DMEM liquid culture medium containing 10% fetal bovine serum (FBS) and 1% double antibodies (penicillin and streptomycin), and adherent growth in a constant temperature incubator at 37°C and 5% CO2 concentration.

[0077] The primers used in the present invention were designed on the NCBI website, and the final primer synthesis work was commissioned to Sangon Biotech Co., Ltd. by sending an e-mail order.

[0078] Example 1 confirmed that BRD7 expression was downregulated in tumor patient tissues and negatively correlated with the high methylation level of the promoter region;

[0079] 1.1 Confirmation that BRD7 is downregulated in tumor patient tissues

[0080] BRD7 has been confirmed to be an important tumor suppressor gene in multiple tumors such as nasopharyngeal carcinoma, breast cancer, lung cancer, cervical cancer, prostate cancer, liver cancer, etc. It is downregulated in tumor tissues and negatively correlated with clinical progression and poor prognosis of tumors. In order to provide strong evidence, we further collected tissues from 16 non-cancer patients and 43 tumor patients, extracted RNA and protein, and detected the expression of BRD7 in tumor patient tissues through RT-qPCR experiments, Western Blot experiments, and agarose gel electrophoresis experiments. The results showed that the expression level of BRD7 in tumor patient tissues was significantly lower than that in non-cancer patients ( Figure 1 AC), indicating that low BRD7 expression can be used as a potential molecular marker for evaluating tumor malignant progression, and targeted activation of BRD7 expression is expected to become a promising molecular strategy for targeted treatment of patients with tumors with low BRD7 expression.

[0081] 1.2 Prediction of BRD7 promoter region methylation level using bioinformatics methods

[0082] In order to further explore the reasons for the downregulation of BRD7 expression, the size, location and methylation of the CpG island in the BRD7 promoter region (2000 bp upstream of the transcription start site) were predicted by bioinformatics on the websites (EMBOSS website and MethPrimer website). The screening conditions were set as CpG island size>100 bp&GC content>50%&Obs / Exp>0.6. The results showed that the CpG island was located 56 bp to 418 bp upstream of the BRD7 transcription start site (-418 / -56)( Figure 1 D), overlaps with the proximal promoter region of BRD7 (-404 / +46).

[0083] 1.3 Methylation-specific PCR confirmed that the BRD7 promoter region was hypermethylated in tumor cell lines and negatively correlated with BRD7 mRNA expression levels

[0084] To further verify the methylation status of the BRD7 promoter region, we extracted genomic DNA from normal epithelial cells NP69 and nine tumor cell lines (6-10B, 5-8F, HNE1, HNE2, CNE1, CNE2, HK1, HONE1, and C666-1) and treated them with bisulfite, in which unmethylated cytosine is converted to uracil, while methylated cytosine remains unchanged. Figure 1 Methylation-specific PCR was performed using the methylation-specific and nonmethylation-specific primers described in E.

[0085] (1) The methylation primers and non-methylation primers required for methylation-specific PCR are shown in Table 1:

[0086] Table 1 Methylation-specific PCR primer sequences

[0087]

[0088] (2) The reaction system (20 μL) is shown in Table 2:

[0089] Table 2 Methylation-specific PCR reaction system

[0090]

[0091] (3) Reaction conditions are shown in Table 3:

[0092] Table 3 Methylation-specific PCR reaction conditions

[0093]

[0094]

[0095] Methylation-specific PCR results showed that the CpG island in the BRD7 promoter region was highly methylated in tumor cell lines, while almost no BRD7 promoter methylation was observed in normal epithelial cells NP69 ( Figure 1 F). The data showed that the BRD7 promoter region was hypermethylated in tumor cell lines and negatively correlated with BRD7 expression levels.

[0096] 1.4 DNA methyltransferase inhibitor decitabine increases BRD7 expression

[0097] Next, we determined the effect of the DNA methyltransferase inhibitor decitabine on BRD7 expression. Decitabine is a methyltransferase inhibitor, an epigenetic modifier that inhibits DNA methyltransferase activity, leading to DNA demethylation (hypomethylation) and gene activation by remodeling “open” chromatin. Figure 1As shown in G, decitabine can bind to DNA methyltransferase, leading to demethylation of BRD7 DNA and subsequent transcriptional activation.

[0098] After the cultured cells grew to 70%-80% density, decitabine was added to treat the cells for 72 hours, and then RNA and protein were extracted, and RT-qPCR and Western Blot experiments were performed respectively. The results showed that decitabine treatment could significantly increase the mRNA and protein expression levels of BRD7 ( Figure 1 H, I). To further investigate the decitabine-induced methylation inhibition, we used methylation-specific PCR (as above) to detect changes in methylation levels in the BRD7 promoter region after decitabine treatment. The results showed that the relative methylation level of the BRD7 promoter in decitabine-treated tumor cells was decreased compared with that in the control group ( Figure 1 J), which once again confirmed that DNA hypermethylation at the BRD7 promoter is a key mechanism for downregulating BRD7 expression.

[0099] 2. Conclusion

[0100] Bioinformatics prediction and methylation-specific PCR confirmed the presence of CpG island hypermethylation in the BRD7 promoter region, which was negatively correlated with the expression level of BRD7, revealing that DNA methylation may be an important mechanism leading to the inhibition of BRD7 expression in tumor cells.

[0101] Example 2, Construction of LentiCRISPRv2 / dCas9-TET1CD-sgRNAs Gene Editing System Targeting

[0102] Hypermethylation of CpG island in BRD7 promoter activates BRD7 expression

[0103] 1. Construction of LentiCRISPRv2 / dCas9-TET1CD-sgRNAs system targeting BRD7 promoter region

[0104] CpG island hypermethylation region

[0105] 1.1 Replace the Cas9 sequence of LentiCRISPRv2 plasmid with dCas9-TET1CD-EGFP

[0106] (1) The overall process of constructing the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system is as follows Figure 2 As shown in A, the LentiCRISPRv2 vector was first double-digested with Xba I and BamH I to remove the Cas9 element in the LentiCRISPRv2 plasmid, and double-digested according to the reaction system (50 μL) in Table 4:

[0107] Table 4 Double enzyme digestion reaction system

[0108]

[0109] In a 200 μL EP tube, add enzyme-free water, template, 10×Q.Cut buffer, and finally the restriction enzyme Quick Cut TM Xba I and Quick Cut TM BamHI, gently blow to mix, and spin off. The whole process is carried out on ice. 37℃ water bath for 2h to complete the enzyme digestion, and then the enzyme digestion product is subjected to agarose gel electrophoresis. The results are as follows Figure 2 As shown in B, what we need is a vector with the Cas9 element removed, so long fragments need to be recovered by gel extraction.

[0110] (2) Gel recovery fragment LentiCRISPRv2-△Cas9 (gel recovery kit purchased from Omega)

[0111] ①Subject the product to DNA gel electrophoresis to separate the target fragment.

[0112] ② Gel cutting: Cut the target band quickly under UV light, and further cut the target band into smaller gel pieces with a blade, and transfer them to a 2mL centrifuge tube. Weigh it on a balance, and then add binding buffer (XP2) in the above EP tube in proportion according to the principle of adding 1mL binding solution to 1mg gel.

[0113] ③ Turn the EP tube upside down to mix the gel and the binding solution thoroughly, then put it into a 65℃ oven. During this period, shake the centrifuge tube every 2 minutes to ensure uniform heating and facilitate full melting of the gel.

[0114] ④ Place the adsorption column in a 2mL EP tube, and add the solution in ③ into the adsorption column at a maximum of 700μL each time, centrifuge at 13000rpm for 1min, pour off the filtrate, and collect all the solution by passing through the column several times.

[0115] ⑤ Add 300 μL of binding buffer (XP2) to the adsorption column, centrifuge at maximum speed for 1 min, pour out the filtrate and put the adsorption column back into the collection tube.

[0116] ⑥ Add 700 μL SPW washing buffer (add anhydrous ethanol according to the instructions before use) to the adsorption column, centrifuge at 13000 rpm for 1 min, repeat once, and discard the filtrate.

[0117] ⑦ Centrifuge at 13000rpm for 2min at room temperature to completely remove the residual liquid in the adsorption column.

[0118] ⑧Put the adsorption column into a new 1.5mL EP tube, open the cap of the adsorption column, and dry it at room temperature for 5-10 minutes to evaporate the anhydrous ethanol remaining on the adsorption column.

[0119] ⑨ Add 10-30 μL of eluent (preheated in a 65°C oven) to the middle of the adsorption column and place at room temperature for 5 minutes.

[0120] ⑩ Cover the adsorption column and centrifuge at room temperature at 13000rpm for 1min. After measuring the concentration, mark the outer wall of the EP tube. Agarose gel electrophoresis test, the results are as follows Figure 2 As shown in C, the specific band in the figure is the LentiCRISPRv2-△Cas9 fragment, which is stored at -20°C for subsequent use.

[0121] (3) PCR amplification of dCas9-TET1CD-EGFP sequence. Table 5 shows the PCR primer sequences.

[0122] Table 5dCas9-TET1CD-EGFP fragment amplification primer sequences

[0123]

[0124] Next, a PCR reaction was performed according to the reaction system (50 μL) in Table 6 to amplify the dCas9-TET1CD-EGFP sequence:

[0125] Table 6 PCR reaction system

[0126]

[0127] The reaction conditions are shown in Table 7:

[0128] Table 7 PCR reaction conditions

[0129]

[0130]

[0131] (4) After the PCR reaction, agarose gel electrophoresis was performed, and the results were as follows: Figure 2 As shown in D, the target band is in the correct position and meets the expected size. The fragment is then purified and recovered according to the following steps for subsequent ligation reactions (the purification kit was purchased from Omega):

[0132] ① Transfer the product to an enzyme-free 1.5 mL or 2 mL centrifuge tube, depending on its specific volume.

[0133] ② Add 4 times the volume of CP Buffer to the above EP tube and vortex.

[0134] ③ Take an adsorption column and a collection tube respectively, place the adsorption column into a 2 mL collection tube, and transfer the solution in step ② to the adsorption column, up to 700 μL each time, centrifuge at 13000 rpm for 1 min at room temperature, pass all the solution through the column several times, and discard the filtrate.

[0135] ④ Add 700 μL DNA washing buffer to the adsorption column, centrifuge at 13000 rpm for 1 min at room temperature, pour out the filtrate in the collection tube and wash again according to the same operation.

[0136] ⑤ Centrifuge at 13000rpm for 2min to remove the residual liquid in the adsorption column.

[0137] ⑥ Place the adsorption column in a new 1.5mL EP tube, open the cap of the adsorption column, and dry it at room temperature for 5-10 minutes to evaporate the anhydrous ethanol remaining on the adsorption column.

[0138] ⑦ Add 15-30 μL of elution solution (preheated in a 65°C oven in advance) to the middle of the adsorption column, place at room temperature for 2 minutes, and centrifuge at 13,000 rpm for 1 minute.

[0139] ⑧Measure the concentration, mark the outer wall of the EP tube, and store it in a -20℃ refrigerator.

[0140] (5) According to the reaction system and reaction conditions in step (1), the dCas9-TET1CD-EGFP fragment (fragment size is 7254 bp) was double-digested with Xba I and BamH I, and the digestion product was purified and recovered and then subjected to agarose gel electrophoresis. The results are as follows Figure 2 E. The bands were located correctly and specifically and were stored at -20°C for subsequent use.

[0141] (6) The LentiCRISPRv2-△Cas9 fragment after double digestion with Xba I and BamH I was connected to the dCas9-TET1CD-EGFP fragment to construct the LentiCRISPRv2 / dCas9-TET1CD vector. The connection system is shown in Table 8:

[0142] Table 8 T4 ligase ligation system

[0143]

[0144] Ligate overnight at 16°C to obtain the LentiCRISPRv2 / dCas9-TET1CD vector plasmid.

[0145] (7) LentiCRISPRv2 / dCas9-TET1CD vector plasmid transformation

[0146] The following operations were all completed in a clean bench dedicated to bacteria (DH5α competent cells were purchased from Beijing Qingke Biotechnology Co., Ltd.)

[0147] ①Put the competent cells stored at -80℃ on ice to dissolve, then transfer to a new 1.5mL EP tube, take 5μL of the ligation product with a pipette and add it to the competent cells, blow evenly and place on ice for 30min.

[0148] ②Immediately place the EP tube in a 42°C water bath for heat shock for 90 seconds, and then incubate on ice for 5 minutes.

[0149] ③ Add 900 μL of non-resistant LB liquid culture medium preheated in a 37°C incubator into the EP tube, gently blow and mix with a pipette, fix the EP tube on a shaker, and activate at 37°C, 160 rpm for 1 hour.

[0150] ④ Take 200 μL of bacterial solution and add it to the ampicillin-resistant LB solid plate. Use a sterilized and cooled smear stick to evenly spread the bacterial solution on the solid plate to ensure complete absorption.

[0151] ⑤ Mark the culture plate with the resistance and expression vector name, place it upside down in a 37°C incubator, and culture it upside down for 12 to 16 hours.

[0152] (8) Picking single clones

[0153] The following operations are all completed in a bacteria-specific clean bench

[0154] ① Take a clean and sterile 2mL EP tube, add 2mL of sterilized LB liquid culture medium, and then add 2μL of antibiotics with the same resistance as the plasmid to the culture medium.

[0155] ② Use a small, enzyme-free and sterile pipette tip to gently pick up a single colony, being careful not to touch other colonies. Then, inject the pipette tip with the bacteria into the LB liquid medium, and mark the time, expression vector name and vector resistance on the side wall of the centrifuge tube.

[0156] ③ Place the 2 mL centrifuge tube in a 37°C shaker at 250 rpm and culture for 12-16 hours.

[0157] (9) PCR detection of bacterial liquid to detect whether the dCas9-TET1CD-EGFP fragment is successfully inserted into the LentiCRISPRv2-△Cas9 vector

[0158] ① Carry out bacterial liquid PCR according to the reaction system (20 μL) in Table 9

[0159] Table 9 Bacterial liquid PCR reaction system

[0160]

[0161]

[0162] ② The reaction conditions are shown in Table 7. After the bacterial solution PCR reaction is completed, agarose gel electrophoresis is performed. Figure 2 As shown in F, it was found that the length of the PCR product of monoclonal bacterial solution No. 5 was in line with expectations. Clone 5 was then sent to Qingke Bio for sequencing, and the sequencing results were completely consistent with the dCas9-TET1CD-EGFP sequence, indicating that the Cas9 sequence of the LentiCRISPR plasmid was successfully replaced with dCas9-TET1CD-EGFP.

[0163] 1.2 Construction of the demethylation plasmid LentiCRISPRv2 / dCas9-TET1CD-sgRNAs targeting the hypermethylated region of the CpG island in the BRD7 promoter region

[0164] One of the main purposes of the present invention is to transform the LentiCRISPRv2 vector so that the transformed LentiCRISPRv2 plasmid can constitutively express sgRNA and dCas9-TET1CD fusion protein that specifically targets the hypermethylated region of the CpG island of the BRD7 promoter, thereby achieving stable BRD7 demethylation and activating BRD7 expression. Therefore, we need to further connect sgRNAs that specifically target the hypermethylated region of the CpG island of the BRD7 promoter to the successfully constructed LentiCRISPRv2 / dCas9-TET1CD vector.

[0165] (1) Five candidate sequences targeting the highly methylated region of the CpG island of the BRD7 promoter were designed based on the target gene sequence. Then, sticky ends for ligation reaction were added to the above five sequences to synthesize sgRNAs sequences. The sequences are shown in Figure 10:

[0166] Table 10 sgRNA sequences targeting the highly methylated region of the CpG island of the BRD7 promoter

[0167]

[0168] The sgRNA1-5 sequences were then sent to Shanghai Bioengineering for synthesis, the powder was centrifuged at 5000 rpm for 5 min, and diluted to 100 μM with sterile water.

[0169] (2) Phosphorylate and anneal each pair of oligonucleotides to anneal the single-stranded sgRNA (sgRNA1-5) to form a double-stranded sgRNA

[0170] ① The reaction system (10 μL) is shown in Table 11:

[0171] Table 11 Single-stranded sgRNA annealing reaction system

[0172]

[0173] ②The reaction conditions are shown in Table 12:

[0174] Table 12 Single-stranded sgRNA annealing reaction conditions

[0175]

[0176] ③ Dilute the annealed double-stranded sgRNA1-5 into sterile water at a ratio of 1:50.

[0177] (3) Digest the lentiviral LentiCRISPRv2 / dCas9-TET1CD plasmid constructed in 1.1 with BsmBI

[0178] ① Enzyme digestion system (10 μL) is shown in Table 13:

[0179] Table 13 BsmBI enzyme digestion system

[0180]

[0181] ② Enzyme digestion at 37℃ for 30min, followed by agarose gel electrophoresis. Figure 2 As shown in G, two specific bands can be seen, of which the short fragment (2kb) is the fragment cut by enzyme, and the long fragment is the fragment we need. Subsequently, the long fragment is recovered by gel electrophoresis and agarose gel electrophoresis is performed again, as shown in FIG. Figure 2 As shown in H, the band position is correct and specific, and the gel recovery product is stored at -20°C for subsequent experiments.

[0182] (4) Construction of LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system targeting the methylation region of BRD7 CpG island

[0183] ① Subsequently, we connected the products recovered after enzyme digestion in step (3) with the double-stranded sgRNA1-5 formed by annealing in step (2), and the connection system is shown in Table 14 (T4 DNA ligase was purchased from Novizan Biotechnology Co., Ltd.):

[0184] Table 14 Connection system

[0185]

[0186] ② Ligate overnight at 16℃, take 5μL of the ligation product for DH5α E. coli transformation, place the plate in a 37℃ bacterial incubator for 12-16h, pick a single clone, and sequence it. Figure 2As shown in Figure 1, the Sanger sequencing results are correct, indicating that sgRNAs (sgRNA1-5) were successfully inserted into the LentiCRISPRv2 / dCas9-TET1CD vector, indicating that the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system targeting the highly methylated region of the BRD7 CpG island was successfully constructed. 2. The LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system can activate the expression of BRD7

[0187] We designed five sgRNAs evenly distributed within the BRD7 CpG island upstream of the BRD7 transcription start site (TSS) ( Figure 3 A) In the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system, sgRNAs recruit the dCas9-TET1CD fusion protein to the hypermethylated region of the BRD7 promoter, thereby inducing DNA demethylation by the TET1 catalytic domain ( Figure 3 B). We then selected nasopharyngeal carcinoma cell lines 5-8F and CNE2 with high methylation levels and low BRD7 expression, and evaluated the activation ability of the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system by lipid transfection. The specific operations are as follows:

[0188] (1) First, we expanded the successfully constructed LentiCRISPRv2 / dCas9-TET1CD-sgRNAs plasmid culture: 15mL of sterilized LB liquid culture medium was taken into a clean and sterile 50mL centrifuge tube, and then 15μL of ampicillin (100mg / mL) and 15μL of bacterial solution were added. The centrifuge tube was fixed in a 37℃ shaker at 250rpm and cultured for 12 to 16 hours. Then, the plasmid was extracted according to the instructions of Tiangen Bio's endotoxin-free plasmid mini-extraction kit, the vector name and plasmid concentration were marked, and stored in a -20℃ refrigerator for subsequent experiments.

[0189] (2) Subsequently, the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system was transfected into nasopharyngeal carcinoma cell lines 5-8F and CNE2.

[0190] ① Digest the adherent cells in good condition in the culture dish and evenly inoculate them in a six-well plate. Add 2 mL of culture medium to each well and culture them in a 37°C constant temperature incubator for 12 hours. The cell confluence is preferably 60%-80%.

[0191] ② Take a sterile 1.5mL EP tube and add 200μL Buffer, 4μL polyplus and 2μg plasmid DNA to the tube in sequence. Vortex the mixture, centrifuge it briefly and let it stand at room temperature for 15 minutes.

[0192] ③ Wash the cells 2-3 times with 1-2 mL D-Hanks solution, add 2 mL fresh culture medium, use a pipette to add the incubated mixture in the EP tube to the six-well plate, gently shake the culture plate to mix evenly, and place it in the incubator to continue culturing.

[0193] ④ 6-8 hours after transfection, remove the original cell culture medium, wash the cells 2-3 times with D-Hanks solution, and add 2mL of new complete culture medium. 36-48 hours after transfection, cells can be collected for subsequent experiments.

[0194] (3) RT-qPCR and Western Blot experiments to detect the effect of LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system on BRD7 expression in tumor cells

[0195] RNA and protein were extracted from 5-8F and CNE2 cells transfected in step (2) 48 hours after transfection, and RT-qPCR and Western Blot experiments were performed. The results showed that in 5-8F cells, compared with the control group, under the traction of sgRNA2 and sgRNA5, the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs system successfully played a demethylation role and promoted the expression of BRD7 mRNA and protein; similarly, in CNE2 cells, under the traction of sgRNA2 and sgRNA5, the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs system also showed a significant activation effect, and both promoted the expression of BRD7 mRNA and protein ( Figure 3 C, D). In summary, sgRNA2 and sgRNA5 can promote the expression of BRD7 gene mRNA and protein in nasopharyngeal carcinoma cells 5-8F and CNE2 after pairing with dCas9-TET1CD, showing consistency.

[0196] (4) Construction of nasopharyngeal carcinoma and breast cancer cell lines stably expressing the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system

[0197] The above results show that among the five sgRNAs targeting the highly methylated region of the BRD7 promoter region, sgRNA2 and sgRNA5 have the most significant activation effect on BRD7 after pairing with dCas9-TET1CD. In addition to low expression in nasopharyngeal carcinoma, BRD7 also plays a tumor suppressor gene function in a variety of tumors such as breast cancer and lung adenocarcinoma cells. Therefore, in order to further verify the effectiveness and broad spectrum of this gene editing system, we constructed nasopharyngeal carcinoma and breast cancer cell lines that stably express LentiCRISPRv2 / dCas9-TET1CD-sgRNA2 and LentiCRISPRv2 / dCas9-TET1CD-sgRNA5. The specific steps are as follows:

[0198] ① Well-growing nasopharyngeal carcinoma cells 5-8F and CNE2 and breast cancer cells MDA-MB-231 and MCF7 were inoculated into a 10 cm culture dish, and plasmid transfection was performed when the 293T cell density was about 60%-80%.

[0199] ② Take a sterile 1.5mL centrifuge tube, add a total of 20μg plasmid and 40μL polyplus in the ratio of target plasmid: psPAX2: pMD2.G = 4:3:1, vortex to mix, centrifuge briefly, and incubate at room temperature for 15 minutes.

[0200] ③ Wash the cells in the 10 cm culture dish 2-3 times with D-Hanks solution, add new 7 mL of complete culture medium to each well, evenly add the incubated plasmid and transfection reagent mixture to the corresponding culture dish, and place it in the incubator for further culture.

[0201] ④ After culturing for 12 hours, add 6-8 mL of fresh culture medium and continue culturing. Collect the lentiviral supernatant 48 hours and 72 hours after transfection.

[0202] ⑤ Virus concentration: Transfer the collected virus supernatant to a 15mL centrifuge tube, centrifuge at 4℃, 3000rpm for 10min, filter into a 50mL centrifuge tube, add 1 / 4 volume of 5×PEG8000 to the virus solution, immediately invert and mix, place on ice, invert 5 times every 30min, and stand overnight in a 4℃ refrigerator. Subsequently, centrifuge at 4℃, 4000g for 20min, aspirate the supernatant, suspend the virus precipitate with 200μL-400μL pre-cooled PBS, and immediately dispense the collected virus into 1.5mL EP tubes and freeze in a -80℃ refrigerator.

[0203] ⑥ Infect target cells: Take the virus out of the -80℃ refrigerator and thaw it. When the target cells grow to the logarithmic phase, add polybrene (8μg / mL) and the virus solution to the virus solution, shake well and place in the incubator for culture. After infection, pay attention to observe the cell state. When the cells are full, they can be passaged, and the cells can be infected again when they grow to the logarithmic growth phase.

[0204] ⑦Antibiotic screening: After the secondary infection, the culture medium was replaced with complete medium, and antibiotic screening was added after 48 hours of culture. There is also a puro screening marker in the gene editing system, so we added 1 mg / mL of puromycin to the infected cells for screening. The screening lasted for about 48 hours. At the same time, it can be observed that almost all the wild-type cells in the control floated up. The cells infected with the lentivirus are the stably transfected cell lines that stably express the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system.

[0205] ⑧ Verification of stable cell lines: Since the constructed LentiCRISPRv2 / dCas9-TET1CD-sgRNAs viral vector is fluorescently labeled, it can be observed under a fluorescence microscope. After the fluorescence efficiency reaches 100%, the antibiotic maintenance concentration is reduced to continue screening and amplifying the infected cells. At the same time, the cells are collected and the expression of BRD7 is detected. The results are as follows Figure 4 As shown in AD, BRD7 expression was significantly increased, as expected, indicating that the stable cell line was successfully constructed.

[0206] (5) RT-qPCR and Western Blot experiments to detect the effect of co-delivery of LentiCRISPRv2 / dCas9-TET1CD-sgRNA2 and LentiCRISPRv2 / dCas9-TET1CD-sgRNA5 on BRD7 expression in tumor cells

[0207] Since previous studies using CRISPR / dCas9 to reactivate gene expression have shown that co-delivery of multiple sgRNAs can increase the level of endogenous gene activation, we transiently transfected LentiCRISPRv2 / dCas9-TET1CD-sgRNA5 into nasopharyngeal carcinoma cells 5-8F and CNE2 stably expressing LentiCRISPRv2 / dCas9-TET1CD-sgRNA2 and breast cancer cells MCF7 and MAD-MB-231 to examine the activation effect of these two sgRNAs combination on BRD7 expression. The results of RT-qPCR and Western Blot experiments showed that compared with the group stably expressing LentiCRISPRv2 / dCas9-TET1CD-sgRNA2 or LentiCRISPRv2 / dCas9-TET1CD-sgRNA5 alone, the combined delivery of LentiCRISPRv2 / dCas9-TET1CD-sgRNA2 and LentiCRISPRv2 / dCas9-TET1CD-sgRNA5 had an additive effect, and the activation effect of BRD7 was more significant ( Figure 4 AD).

[0208] 3. Conclusion

[0209] The LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system (LentiCRISPRv2 / dCas9-TET1CD-sgRNA2 and LentiCRISPRv2 / dCas9-TET1CD-sgRNA5) can demethylate the CpG island hypermethylated region of the BRD7 promoter region, thereby activating BRD7 expression; and the combined delivery of sgRNA2 and sgRNA5 has an additive effect, and the activation effect of BRD7 is more significant. At the same time, this gene editing system has a broad spectrum, and plays a role in activating the expression of the tumor suppressor gene BRD7 in multiple tumors such as nasopharyngeal carcinoma and breast cancer, providing a basis for precise tumor treatment.

[0210] Example 3, in vitro experiments confirmed that the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system can inhibit the proliferation and cloning of BRD7 low-expressing tumor cells

[0211] 1.1CCK-8 cell proliferation assay

[0212] (1) The nasopharyngeal carcinoma and breast cancer stable transfected cell lines that successfully stably expressed the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system were diluted to 1000 cells / 100 μL culture medium per well (prepare 35 wells for each group) and inoculated in a 96-well plate (D-Hanks solution was added to the outermost circle of the 96-well plate to reduce the evaporation of the culture medium). Each group had 5 replicate wells (based on 6 days), and each group was inoculated with 30 wells in total. When adding samples, they should be pipetted slowly while adding samples to prevent uneven addition caused by cell precipitation. The plates were placed in a 37°C incubator for culture.

[0213] (2) After the cells adhered, add 10 μL of CCK-8 reagent to each well at a ratio of CCK-8: medium volume = 1:10 under light-proof conditions. Gently shake the 96-well plate to mix the solution evenly and place it in an incubator for 2 h.

[0214] (4) Take out the 96-well plate and use an ELISA reader to measure the absorbance of the culture medium in 5 replicate wells in each group at 450 nm and record it as the data for day 0. Thereafter, measure it every 24 hours and record it as day 1, day 2, etc.

[0215] (5) After all data were measured, the data on day 0 were normalized, the cell proliferation rate was calculated, and the graph was drawn using GraphPad Prism software. Figure 5 As shown in A, in nasopharyngeal carcinoma cells 5-8F and CNE2 and breast cancer cells MDA-MB-231 and MCF7, compared with the control group, the LentiCRISPRv2 / dCas9-TET1CD-sgRNA2 stable expression group or the LentiCRISPRv2 / dCas9-TET1CD-sgRNA5 stable expression group inhibited the proliferation ability of nasopharyngeal carcinoma cells and breast cancer cells, and the inhibitory effect of the dCas9-TET1CD-sgRNA2 and dCas9-TET1CD-sgRNA5 co-expression group was more significant.

[0216] 1.2 Clone formation assay

[0217] (1) The nasopharyngeal carcinoma and breast cancer stable transfected cell lines that successfully stably expressed the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system were diluted to 1000 cells / 2 mL culture medium per well, and 3 replicates were plated evenly in 6-well plates. The plates were cultured in a 37°C incubator for 7-14 days. During the culture period, the plates were carefully observed. If the culture medium was reduced, 1 mL of culture medium was added to each well.

[0218] (3) When the cells proliferate into clones of more than 50 cells, remove them from the incubator and wash them three times with 1× PBS, each time for 5 min.

[0219] (4) Fixation: Fix the cells with 4% paraformaldehyde at room temperature for 20 min.

[0220] (5) Staining: Discard the supernatant, add 1 mL of crystal violet to each well, stain for 5-10 min, rinse with distilled water until no crystal violet remains, dry and take photos.

[0221] (6) After taking photos and recording, count the number of effective cell clones in each group and analyze the data. Figure 5 As shown in B, in nasopharyngeal carcinoma cells 5-8F and CNE2 and breast cancer cells MDA-MB-231 and MCF7, compared with the control group, the LentiCRISPRv2 / dCas9-TET1CD-sgRNA2 stable expression group or the LentiCRISPRv2 / dCas9-TET1CD-sgRNA5 stable expression group inhibited the cloning ability of nasopharyngeal carcinoma cells and breast cancer cells, and the inhibitory effect of the dCas9-TET1CD-sgRNA2 and dCas9-TET1CD-sgRNA5 co-expression group was more significant.

[0222] 2. Conclusion

[0223] In vitro experiments confirmed that the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system (LentiCRISPRv2 / dCas9-TET1CD-sgRNA2 and LentiCRISPRv2 / dCas9-TET1CD-sgRNA5) can inhibit the proliferation and clone formation ability of tumor cells with low BRD7 expression, and the inhibitory effect of co-expression of dCas9-TET1CD-sgRNA2 and dCas9-TET1CD-sgRNA5 is more significant, indicating that this gene editing system can successfully activate the expression of BRD7 and promote the anti-cancer effect of BRD7.

[0224] Example 4, in vivo experiments confirmed that the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system can inhibit tumor growth in vivo

[0225] 1.1 Materials and methods

[0226] Twenty female BALB / C nude mice, 4 weeks old, weighing 19±2 g, were purchased from Beijing Weitonglihua Laboratory Animal Technology Co., Ltd. All nude mice passed the quality inspection and were raised under specific pathogen-free (SPF) conditions at the Department of Animal Science, Central South University.

[0227] 1.2 Construction of nude mouse subcutaneous transplanted tumor model

[0228] (1) According to the number of nude mice in each group and the number of cells required to be injected into each mouse, nasopharyngeal carcinoma cell CNE2 was used to prepare control group cells (LentiCRISPR / dCas9-TET1CD-sgNC) and experimental group cells. The experimental group was divided into 3 groups: a group that stably expressed LentiCRISPRv2 / dCas9-TET1CD-sgRNA2, a group that stably expressed LentiCRISPRv2 / dCas9-TET1CD-sgRNA5, and a group that co-expressed LentiCRISPRv2 / dCas9-TET1CD-sgRNA2 and LentiCRISPRv2 / dCas9-TET1CD-sgRNA5.

[0229] (2) Each group had 5 nude mice, and each nude mouse was prepared with 8×10 6 When the nude mice grow to about 5 weeks old, use insulin injection to inoculate the cell suspension into the subcutaneous part above the axilla of the right forelimb of the nude mice.

[0230] (3) After the tumor grows, use a vernier caliper to record the length and width of the tumor every 3 days to calculate the tumor growth volume.

[0231] (4) In accordance with animal ethics requirements, after the cell tumors grew to a certain size, the mice were anesthetized with isoflurane, and the nude mice were photographed. Then, the nude mice in each group were killed, the tumors were removed, photographed, and the weight of all tumors was measured. Figure 6 As shown in AC, compared with the control group, the LentiCRISPRv2 / dCas9-TET1CD-sgRNA2 stable expression group or the LentiCRISPRv2 / dCas9-TET1CD-sgRNA5 stable expression group can significantly inhibit tumor growth rate and reduce tumor weight, and the dCas9-TET1CD-sgRNA2 and dCas9-TET1CD-sgRNA5 co-expression group played an additive role, and the inhibitory effect was more significant.

[0232] 1.3 Immunohistochemistry assay to detect the effect of LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system on the expression of BRD7 and its downstream target molecules

[0233] (1) The mouse tumor tissue was fixed, dehydrated, transparentized, wax-impregnated, and embedded before being sliced ​​and stored at -20°C.

[0234] (2) Paraffin sections stored at -20°C were placed in a 65°C oven overnight to melt the surface paraffin.

[0235] (3) Dewaxing: xylene I dewaxing for 10 min, xylene II dewaxing for 10 min

[0236] (4) Gradient alcohol washing: 100% alcohol, 5 min → 100% alcohol, 5 min → 90% alcohol, 5 min → 85% alcohol, 5 min → 85% alcohol, 5 min → 85% alcohol, 5 min → 75% alcohol, 5 min → 50% alcohol, 5 min → enzyme-free water, 5 min

[0237] (5) Transfer the slices to 1× PBS and wash for 5 min. Repeat 3 times.

[0238] (6) Antigen repair: Use EDTA or sodium citrate for antigen repair. The antigen repair solution should be boiled in advance. Cover the slices with a film during the antigen repair process to prevent evaporation and drying of the slices. Use a microwave oven at medium-low heat for 20 minutes, and add antigen repair solution every 10 minutes or so. After repair, take the slices out of the microwave and let them cool naturally at room temperature.

[0239] (7) Wash the sections in 1× PBS for 5 min, repeat 3 times.

[0240] (8) Block endogenous peroxidase: Add an appropriate amount of peroxidase blocker (reagent 1) according to the size of the tissue and incubate at room temperature for 30 minutes.

[0241] (9) Wash the sections in 1× PBS for 5 min, repeat three times.

[0242] (10) Blocking: Add an appropriate amount of nonspecific blocking agent (reagent 2) according to the size of the tissue and block at room temperature for 30 minutes.

[0243] (11) Incubation with primary antibody: Shake off the excess blocking solution on the slices, do not wash, prepare the primary antibody with antibody diluent according to the dilution ratio of immunohistochemical antibody in the instruction manual, add an appropriate amount of primary antibody according to the size of the tissue, place in a humidified box, add water to the bottom of the humidified box to prevent the slices from drying out. Place in a 4°C refrigerator and incubate overnight (14-16 hours).

[0244] (12) Washing the primary antibody: Soak the slices in 1× PBS, place them on a shaker, adjust the shaker speed to 50 rpm, shake and wash for 15 minutes, and repeat 3 times.

[0245] (13) Incubation with secondary antibody: Add one drop of the secondary antibody solution (reagent 3) in the ready-to-use rapid immunohistochemistry Max Vision kit to each tissue and incubate at room temperature for 30 min.

[0246] (14) Shake off the secondary antibody solution on the slice, add an appropriate amount of peroxidase solution (reagent 4) according to the tissue size, and incubate at room temperature for 10 min.

[0247] (15) Washing the secondary antibody: Soak the slices in 1× PBS, place them on a shaker, and wash them three times with 1× PBS, each time for 5 min. Then, place the slices in ddH2O.

[0248] (16) DAB color development, hematoxylin counterstaining, blueing, sealing, photographing, and scoring. Figure 6 As shown in D, compared with the control group, the LentiCRISPRv2 / dCas9-TET1CD-sgRNA2 stable expression group or the LentiCRISPRv2 / dCas9-TET1CD-sgRNA5 stable expression group can significantly activate the expression of BRD7, and the dCas9-TET1CD-sgRNA2 and dCas9-TET1CD-sgRNA5 co-expression group played a synergistic role, and the activation effect was more significant. The expression of some cell proliferation, cycle and apoptosis-related molecules in nude mouse tumors was further detected by immunohistochemistry, and it was found that the LentiCRISPRv2 / dCas9-TET1CD-sgRNA2 stable expression group or the LentiCRISPRv2 / dCas9-TET1CD-sgRNA5 stable expression group could inhibit the expression of Ki67 and promote the expression of P21, c-PARP and other molecules; while the co-expression group of the two significantly enhanced the inhibition or promotion of the expression of the above molecules.

[0249] 3. Conclusion

[0250] In summary, the in vivo experimental results further prove that the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system activates BRD7 expression by targeting the CpG island hypermethylation region of the BRD7 promoter region, thereby inhibiting the growth of tumors in vivo, and the inhibitory effect of sgRNA2 and sgRNA5 co-delivery is more significant. Immunohistochemistry experiments also confirmed that the gene editing system can significantly activate the expression of BRD7, and then inhibit the malignant progression of tumors by regulating the expression of downstream proliferation, cycle and apoptosis-related molecules, providing a powerful molecular strategy for the personalized treatment of tumor patients.

[0251] SEQ NO:1

[0252] dCas9-TET1CD-EGFP sequence:

[0253] ATGAGCCCCAAGAAGAAGAGAAAGGTGGAGGCCAGCGACAAGAAGTACAGCA

[0254] TCGGCCTGGCCATCGGCACCAACTCTGTGGGCTGGGCCGTGATCACCGACGAG

[0255] TACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGACCGGCACAG

[0256] CATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAACAGCCG

[0257] AGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAGAA

[0258] CCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGA

[0259] CAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGC

[0260] ACGAGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAG

[0261] AAGTACCCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAA

[0262] GGCCGACCTGCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGG

[0263] CCACTTCCTGATCGAGGGCGACCTGAACCCCGACAACAGCGACGTGGACAAGC

[0264] TGTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTCGAGGAAAACCCCATCA

[0265] ACGCCAGCGGCGTGGACGCCAAGGCCATCCTGTCTGCCAGACTGAGCAAGAGC

[0266] AGACGGCTGGAAAATCTGATCGCCCAGCTGCCCGGCGAGAAGAAGAATGGCCT

[0267] GTTCGGCAACCTGATTGCCCTGAGCCTGGGCCTGACCCCCAACTTCAAGAGCA

[0268] ACTTCGACCTGGCCGAGGATGCCAAACTGCAGCTGAGCAAGGACACCTACGAC

[0269] GACGACCTGGACAACCTGCTGGCCCAGATCGGCGACCAGTACGCCGACCTGTT

[0270] TCTGGCCGCCAAGAACCTGTCCGACGCCATCCTGCTGAGCGACATCCTGAGAGT

[0271] GAACACCGAGATCACCAAGGCCCCCCTGAGCGCCTCTATGATCAAGAGATACGA

[0272] CGAGCACCACCAGGACCTGACCCTGCTGAAAGCTCTCGTGCGGCAGCAGCTGC

[0273] CTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAACGGCTACGCCGGC

[0274] TACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCATC

[0275] CTGGAAAAGATGGACGGCACCGAGGAACTGCTCGTGAAGCTGAACAGAGAGG

[0276] ACCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCAGATC

[0277] CACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATTC

[0278] CTGAAGGACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTA

[0279] CTACGTGGGCCCTCTGGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAA

[0280] AGAGCGAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGG

[0281] CGCTTCCGCCCAGAGCTTCATCGAGCGGATGACCAACTTCGATAAGAACCTGCC

[0282] CAACGAGAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGT

[0283] ATAACGAGCTGACCAAAGTGAAATACGTGACCGAGGGAATGAGAAAGCCCGCC

[0284] TTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCTGCTGTTCAAGACCAA

[0285] CCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGAGT

[0286] GCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGATCGGTTCAACGCCTCCCTGG

[0287] GCACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACTTCCTGGACAATG

[0288] AGGAAAACGAGGACATTCTGGAAGATATCGTGCTGACCCTGACACTGTTTGAG

[0289] GACAGAGAGATGATCGAGGAACGGCTGAAAACCTATGCCCACCTGTTCGACGA

[0290] CAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGGCAGGCTG

[0291] AGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCGGCAAGACAATCCT

[0292] GGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAAACTTCATGCAGCTGATCCA

[0293] CGACGACAGCCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGTGTCCGGCC

[0294] AGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGCCATTA

[0295] AGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTGATG

[0296] GGCCGGCACAAGCCCGAGAACATCGTGATCGAAATGGCCAGAGAGAACCAGA

[0297] CCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGA

[0298] GGGCATCAAAGAGCTGGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAAC

[0299] ACCCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGA

[0300] TATGTACGTGGACCAGGAACTGGACATCAACCGGCTGTCCGACTACGATGTGGA

[0301] CGCTATCGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGCT

[0302] GACCAGAAGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAG

[0303] GTCGTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGAT

[0304] TACCCAGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCG

[0305] AACTGGATAAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAACCCGGCAGATC

[0306] ACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGAACACTAAGTACGACGA

[0307] GAATGACAAGCTGATCCGGGAAGTGAAAGTGATCACCCTGAAGTCCAAGCTGG

[0308] TGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCGAGATCAACAACT

[0309] ACCACCACGCCCACGACGCCTACCTGAACGCCGTCGTGGGAACCGCCCTGATC

[0310] AAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGACTACAAGGTGTA

[0311] CGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCG

[0312] CCAAGTACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCGAGATTACCCT

[0313] GGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACC

[0314] GGGGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGCT

[0315] GAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCT

[0316] TCAGCAAAGAGTCTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGCCAGA

[0317] AAGAAGGACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGC

[0318] CTATTCTGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGA

[0319] AGAGTGTGAAAGAGCTGCTGGGGATCACCATCATGGAAAGAAGCAGCTTCGAG

[0320] AAGAATCCCATCGACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAGGA

[0321] CCTGATCATCAAGCTGCCTAAGTACTCCCTGTTCGAGCTGGAAAACGGCCGGAA

[0322] GAGAATGCTGGCCTCTGCCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGC

[0323] CCTCCAAATATGTGAACTTCCTGTACCTGGCCAGCCACTATGAGAAGCTGAAGG

[0324] GCTCCCCCGAGGATAATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAGCAC

[0325] TACCTGGACGAGATCATCGAGCAGATCAGCGAGTTCTCCAAGAGAGTGATCCTG

[0326] GCCGACGCTAATCTGGACAAAGTGCTGTCCGCCTCAACAAGCACCGGGATAA

[0327] GCCCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTTACCCTGACCAATCT

[0328] GGGAGCCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGACCGGAAGAGGT

[0329] ACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCCACCAGAGCATCACC

[0330] GGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAGGCGACAGCGCTGG

[0331] AGGAGGTGGAAGCGGAGGAGGAGGAAGCGGAGGAGGAGGTAGCGGACCTAA

[0332] GAAAAAGAGGAAGGTGGCGGCCGCTGGATCCCTGCCCACCTGCAGCTGTCTTG

[0333] ATCGAGTTATACAAAAAGACAAAGGCCCATATTATACACACCTTGGGGCAGGAC

[0334] CAAGTGTTGCTGCTGTCAGGGAAATCATGGAGAATAGGTATGGTCAAAAAGGA

[0335] AACGCAATAAGGATAGAAATAGTAGTGTACACCGGTAAAGAAGGGAAAAGCTC

[0336] TCATGGGTGTCCAATTGCTAAGTGGGTTTTAAGAAGAAGCAGTGATGAAGAAA

[0337] AAGTTCTTTGTTTGGTCCGGCAGCGTACAGGCCACCACTGTCCAACTGCTGTGA

[0338] TGGTGGTGCTCATCATGGTGTGGGATGGCATCCCTCTTCCAATGGCCGACCGGC

[0339] TATACACAGAGCTCACAGAGAATCTAAAGTCATACAATGGGCACCCTACCGACA

[0340] GAAGATGCACCCTCAATGAAAATCGTACCTGTACATGTCAAGGAATTGATCCAG

[0341] AGACTTGTGGAGCTTCATTCTCTTTTGGCTGTTCATGGAGTATGTACTTTAATGG

[0342] CTGTAAGTTTGGTAGAAGCCCAAGCCCCAGAAGATTTAGAATTGATCCAAGCTC

[0343] TCCCTTACATACCTACTATGAAAGAATTACTAAAGGACGTAATCCAGAAAGAAG

[0344] ATATATGAAACCGGAACGAATCAGTCCGGGACACGAGGCCATGGAAAAAAACC

[0345] TTGAAGATAACTTACAGAGTTTGGCTACACGATTAGCTCCAATTTATAAGCAGTA

[0346] TGCTCCAGTAGCTTACCAAAATCAGGTGGAATATGAAAATGTTGCCCGAGAATG

[0347] TCGGCTTGGCAGCAAGGAAGGTCGTCCCTTCTCTGGGGTCACTGCTTGCCTGGA

[0348] CTTCTGTGCTCATCCCCACAGGGACATTCACAACATGAATAATGGAAGCACTGT

[0349] GGTTTGTACCTTAACTCGAGAAGATAACCGCTCTTTGGGTGTTATTCCTCAAGAT

[0350] GAGCAGCTCCATGTGCTACCTCTTTATAAGCTTTCAGACACAGATGAGTTTGGCT

[0351] CCAAGGAAGGAATGGAAGCCAAGATCAAATCTGGGGCCATCGAGGTCCTGGCA

[0352] CCCCGCCGCAAAAAAAGAACGTGTTTCACTCAGCCTGTTCCCCGTTCTGGAAA

[0353] GAAGAGGGCTGCGATGATGACAGAGGTTCTTGCACATAAGATAAGGGCAGTGG

[0354] AAAAGAAACCTATTCCCCGAATCAAGCGGAAGAATAACTCAACAACAACAAAC

[0355] AACAGTAAGCCTTCGTCACTGCCAACCTTAGGGAGTAACACTGAGACCGTGCA

[0356] ACCTGAAGTAAAAAGTGAAACCGAACCCCATTTTATCTTAAAAAGTTCAGACAA

[0357] CACTAAAACTTATTCGCTGATGCCATCCGCTCCTCACCCAGTGAAAGAGGCATC

[0358] TCCAGGCTTCTCCTGGTCCCCGAAGACTGCTTCAGCCACACCAGCTCCACTGAA

[0359] GAATGACGCAACAGCCTCATGCGGGTTTTCAGAAAGAAGCAGCACTCCCCACT

[0360] GTACGATGCCTTCGGGAAGACTCAGTGGTGCCAATGCAGCTGCTGCTGATGGCC

[0361] CTGGCATTTCACAGCTTGGCGAAGTGGCTCCTCTCCCCACCCTGTCTGCTCCTG

[0362] TGATGGAGCCCCTCATTAATTCTGAGCCTTCCACTGGTGTGACTGAGCCGCTAA

[0363] CGCCTCATCAGCCAAACCACCAGCCCTCCTTCCTCACCTCTCCTCAAGACCTTG

[0364] CCTCTTCTCCAATGGAAGAAGATGAGCAGCATTCTGAAGCAGATGAGCCTCCAT

[0365] CAGACGAACCCCTATCTGATGACCCCCTGTCACCTGCTGAGGAGAAATTGCCCC

[0366] ACATTGATGAGTATTGGTCAGACAGTGAGCACATCTTTTTGGATGCAAATATTGG

[0367] TGGGGTGGCCATCGCACCTGCTCACGGCTCGGTTTTGATTGAGTGTGCCCGGCG

[0368] AGAGCTGCACGCTACCACTCCTGTTGAGCACCCCAACCGTAATCATCCAACCCG

[0369] CCTCTCCCTTGTCTTTTACCAGCACAAAAACCTAAATAAGCCCCAACATGGTTTT

[0370] GAACTAAACAAGATTAAGTTTGAGGCTAAAGAAGCTAAGAATAAAGAAAATGAA

[0371] GGCCTCAGAGCAAAAAGACCAGGCAGCTAATGAAGGTCCAGAACAGTCCTCTG

[0372] AAGTAAATGAATTGAACCAAATTCCTTCTCATAAAGCATTAACATTAACCCATGA

[0373] CAATGTTGTCACCGTGTCCCCTTATGCTCTCACACACGTTGCGGGGCCCTATAAC

[0374] CATTGGGTCGCTAGCGGCAGTGGAGAGGGCAGAGGAAGTCTGCTAACATGCGG

[0375] TGACGTCGAGGAGAATCCTGGCCCAGTGAGCAAGGGCGAGGAGCTGTTCACCG

[0376] GGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC

[0377] AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAA

[0378] GTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCAC

[0379] CCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGC

[0380] ACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCT

[0381] TCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGC

[0382] GACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGG

[0383] CAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATAT

[0384] CATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACA

[0385] ACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC

[0386] ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTC

[0387] CGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGT

[0388] TCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAA。

Claims

1. A method for preparing a LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system based on the tumor suppressor gene BRD7, characterized in that: The steps include: The Cas9 sequence of the LentiCRISPRv2 plasmid was replaced with dCas9-TET1CD-EGFP to obtain the LentiCRISPRv2 / dCas9-TET1CD vector; sgRNAs specifically targeting the highly methylated region of the CpG island of the BRD7 promoter were further connected to the LentiCRISPRv2 / dCas9-TET1CD vector.

2. The preparation method according to claim 1, characterized in that: (1) First, the LentiCRISPRv2 vector is digested with enzymes to remove the Cas9 element in the LentiCRISPRv2 vector, and the LentiCRISPRv2-△Cas9 fragment with Cas9 removed is recovered by gel; (2) PCR amplification of dCas9-TET1CD-EGFP sequence, wherein the dCas9-TET1CD-EGFP sequence is shown in SEQ NO: 1; (3) connecting the LentiCRISPRv2-△Cas9 fragment from which Cas9 was removed in step (1) with the dCas9-TET1CD-EGFP fragment amplified in step (2) to construct a LentiCRISPRv2 / dCas9-TET1CD vector; (4) Designing sgRNAs targeting the highly methylated region of the CpG island of the BRD7 promoter based on the target gene sequence; annealing the single-stranded sgRNA to form a double-stranded sgRNA; (5) Enzyme digestion step (3) constructed LentiCRISPRv2 / dCas9-TET1CD vector; (6) Connecting the long fragment product recovered after enzyme digestion in step (5) with the double-stranded sgRNA formed by annealing in step (4) to obtain LentiCRISPRv2 / dCas9-TET1CD-sgRNAs.

3. The preparation method according to claim 2, characterized in that: Specifically include: First, the LentiCRISPRv2 vector was double-digested with Xba I and BamH I to remove the Cas9 element in the LentiCRISPRv2 vector, and the fragment LentiCRISPRv2-△Cas9 was recovered by gel-gel; Then PCR amplified the dCas9-TET1CD-EGFP sequence; The LentiCRISPRv2-△Cas9 fragment was connected to the dCas9-TET1CD-EGFP fragment using T4 DNA ligase to construct the LentiCRISPRv2 / dCas9-TET1CD vector; Design sgRNAs targeting the highly methylated region of the CpG island of the BRD7 promoter according to the target gene sequence, and anneal the single-stranded sgRNA to form a double-stranded sgRNA; Digest the constructed LentiCRISPRv2 / dCas9-TET1CD plasmid with BsmBI; T4 DNA ligase was used to ligate the product recovered after digestion of LentiCRISPRv2 / dCas9-TET1CD plasmid with the double-stranded sgRNA formed by annealing.

4. The preparation method according to any one of claims 1 to 3, characterized in that PCR amplification primer sequences:

5. The preparation method according to any one of claims 1 to 4, characterized in that: The constructed LentiCRISPRv2 / dCas9-TET1CD vector plasmid was transformed into DH5α Escherichia coli competent cells, and single clones were picked for resistance screening. The bacterial liquid PCR was used to detect whether the dCas9-TET1CD-EGFP fragment was successfully inserted into the LentiCRISPRv2-△Cas9 vector; The product recovered after BsmBI digestion of LentiCRISPRv2 / dCas9-TET1CD plasmid and the ligation product of the double-stranded sgRNA formed by annealing were used for DH5α Escherichia coli transformation, resistance screening, picking single clones, and sequencing to determine whether the sgRNA was successfully inserted into the LentiCRISPRv2 / dCas9-TET1CD vector.

6. The preparation method according to any one of claims 1 to 5, characterized in that: The preparation of the lentiviral system mainly includes: viral packaging plasmids psPAX2 and pMD2.G, reagent polyplus required for transfection of the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system, and viral concentrate PEG8000.

7. LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system, characterized in that: The method is prepared by any one of claims 1 to 6.

8. The use of the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system according to claim 7, characterized in that: Preparation of tumor therapeutic preparations.

9. The use according to claim 8, characterized in that: The tumors include: nasopharyngeal carcinoma, breast cancer, lung cancer, cervical cancer and other tumor types in which BRD7 is lowly expressed.

10. The use of the LentiCRISPRv2 / dCas9-TET1CD-sgRNAs gene editing system according to claim 7, characterized in that: Preparation of a preparation for activation of the tumor suppressor gene BRD7.